CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Still a Buy?

Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC) rose 1% during trading on Thursday . The company traded as high as $1.03 and last traded at $1.03. Approximately 26,434 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,726,968 shares. The stock had previously closed at $1.02.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of CytoMed Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CytoMed Therapeutics currently has an average rating of “Sell”.

CytoMed Therapeutics Trading Up 1.0%

The stock’s fifty day moving average price is $1.19 and its 200-day moving average price is $1.71.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.